PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.81 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.38.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.81, a 74.36% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $10.96, a 2573.17% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.41.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.75, a 36.44% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $2.81 10-K · filed 2026-03-16 | |||||
| 2024-12-31 | $10.96 10-K/A · filed 2025-03-28 | |||||
| 2023-12-31 | $0.41 10-K · filed 2024-03-28 | |||||
| 2023-09-30 | $0.51 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | $0.51 10-Q · filed 2023-08-11 | |||||
| 2023-03-31 | $0.38 10-Q · filed 2023-05-15 | |||||
| 2022-12-31 | $0.34 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | $0.34 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $0.30 10-Q · filed 2023-08-11 | $0.75 10-K · filed 2024-03-28 | ||||
| 2021-06-30 | $1.18 10-KT · filed 2023-05-01 | |||||
| 2020-06-30 | $0.61 10-KT · filed 2023-05-01 | |||||
| 2019-06-30 | $0.44 10-K · filed 2021-09-27 | |||||
| 2018-06-30 | $0.47 10-K · filed 2020-09-25 | |||||
| 2017-06-30 | $0.61 10-K · filed 2019-09-27 | |||||
| 2016-06-30 | $0.87 10-K · filed 2018-09-26 | |||||
| 2015-06-30 | $1.41 10-K · filed 2017-09-28 | |||||
| 2014-06-30 | $1.81 10-K · filed 2016-09-09 | $1.92 10-K · filed 2014-09-29 | ||||
| 2013-09-06 | $0.59 10-Q · filed 2015-05-15 | |||||
| 2013-09-05 | $0.58 10-Q · filed 2015-05-15 | |||||
| 2012-06-30 | $0.80 10-K · filed 2013-09-30 | |||||
| 2011-06-30 | $0.99 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |